Published in Eur Urol on January 12, 2007
Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol (2009) 5.11
Update on the medical treatment of metastatic renal cell carcinoma. Eur Urol (2008) 2.80
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Urol (2007) 2.21
Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol (2010) 2.18
Radiation recall: a well recognized but neglected phenomenon. Cancer Treat Rev (2005) 1.85
miR-143 interferes with ERK5 signaling, and abrogates prostate cancer progression in mice. PLoS One (2009) 1.84
Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors. J Clin Oncol (2004) 1.67
Targeted therapy in renal cell carcinoma. World J Urol (2008) 1.56
Gemcitabine and docetaxel as front-line chemotherapy in patients with carcinoma of an unknown primary site. Cancer (2004) 1.54
Complete clinical and biological response to zoledronic acid in castrate-resistant prostate cancer metastatic to bone. Anticancer Drugs (2012) 1.45
Abrogation of de novo lipogenesis by stearoyl-CoA desaturase 1 inhibition interferes with oncogenic signaling and blocks prostate cancer progression in mice. Mol Cancer Ther (2010) 1.42
Peroxisome proliferator-activated receptor gamma regulates E-cadherin expression and inhibits growth and invasion of prostate cancer. Mol Cell Biol (2006) 1.37
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. Eur Urol (2007) 1.37
[Standards, Options and Recommendations for the management of patient with carcinoma of unknown primary site]. Bull Cancer (2002) 1.24
Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy. Cancer Res (2010) 1.18
5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma. Oncology (2011) 1.16
Do patients with advanced urothelial carcinoma benefit from weekly paclitaxel chemotherapy? A GETUG phase II study. Clin Genitourin Cancer (2009) 0.97
Inter- and intraindividual variabilities in pharmacokinetics of fentanyl after repeated 72-hour transdermal applications in cancer pain patients. Ther Drug Monit (2005) 0.96
Liver metastases in prostate carcinoma: clinical characteristics and outcome. BJU Int (2006) 0.96
Prognostic factors in women treated for ovarian yolk sac tumour: a retrospective analysis of 84 cases. Eur J Cancer (2010) 0.90
[Cabazitaxel for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: the TROPIC study in France]. Bull Cancer (2012) 0.87
Population pharmacokinetics of melphalan, infused over a 24-hour period, in patients with advanced malignancies. Cancer Chemother Pharmacol (2004) 0.86
Treatment with sunitinib enabled complete resection of massive lymphadenopathy not previously amenable to excision in a patient with renal cell carcinoma. Eur Urol (2008) 0.84
A mucoepidermoid carcinoma in a young man with intellectual disability: review of oral cancer in people with intellectual disability. Oral Surg Oral Med Oral Pathol Oral Radiol (2013) 0.84
Nonseminomatous germ cell tumors: assessing the need for postchemotherapy contralateral pulmonary resection in patients with ipsilateral complete necrosis. J Thorac Cardiovasc Surg (2009) 0.84
Individual adaptive dosing of topotecan in ovarian cancer. Clin Cancer Res (2002) 0.83
Sensitive HPLC-fluorescence method for irinotecan and four major metabolites in human plasma and saliva: application to pharmacokinetic studies. Clin Chem (2003) 0.83
Cetuximab in advanced bladder cancer. J Clin Oncol (2013) 0.83
Hepatic metastases from carcinomas of unknown primary site. Gastroenterol Clin Biol (2005) 0.82
A phase II study of irinotecan in patients with advanced renal cell carcinoma. Cancer (2003) 0.82
Targeted therapies in metastatic renal cancer in 2009. BJU Int (2009) 0.82
Kidney cancer pathology in the new context of targeted therapy. Pathobiology (2011) 0.81
Targeted therapies in non-muscle-invasive bladder cancer according to the signaling pathways. Urol Oncol (2009) 0.80
Two cases of non-small-cell lung cancer with rare complex mutation of EGFR exon 18 but different response to targeted therapy. J Thorac Oncol (2014) 0.80
Blood and plasma pharmacokinetics of vinorelbine in elderly patients with advanced metastatic cancer. Cancer Chemother Pharmacol (2002) 0.80
[What is the objective of second-line chemotherapy after failure of first-line chemotherapy in hormone-resistant metastatic prostate?]. Prog Urol (2006) 0.79
A lower risk of dying from urological cancer in Down syndrome: clue for cancer protecting genes on chromosome 21. Urol Int (2009) 0.79
Prognostic factors for first recurrence in patients with retroperitoneal sarcoma. Urol Oncol (2006) 0.79
Awareness on oral cancer in people with intellectual disability. Oral Oncol (2012) 0.79
Assessment of solid cancer treatment feasibility in older patients: a prospective cohort study. Oncologist (2014) 0.79
[Penile tumors]. Prog Urol (2007) 0.79
A limited-sampling strategy to estimate individual pharmacokinetic parameters of vinorelbine in elderly patients with advanced metastatic cancer. Anticancer Drugs (2002) 0.78
Abiraterone acetate withdrawal syndrome: does it exist? Case Rep Oncol (2012) 0.78
Quality of life of 1276 elderly patients with prostate cancer, starting treatment with a gonadotropin-releasing hormone agonist: results of a French observational study. Aging Male (2014) 0.77
[Renal cell carcinoma and antiangiogenic therapies]. Presse Med (2007) 0.77
Prognostic factors for cases with metastatic renal cell carcinoma in the era of targeted medicine. Int J Urol (2009) 0.77
[Role of PPARgamma in the control of prostate cancer growth: a new approach for therapy]. Bull Cancer (2007) 0.76
[Gemcitabine and ionizing radiations: radiosensitization or radio-chemotherapy combination]. Bull Cancer (2002) 0.76
[Chemotherapy in castrate-resistant metastatic prostate cancer]. Rev Prat (2013) 0.76
Inter- and intra-individual variability in transdermal fentanyl absorption in cancer pain patients. Oncol Rep (2005) 0.76
[Testicular tumors]. Prog Urol (2007) 0.76
Editorial comment on: postchemotherapy retroperitoneal lymph node dissection in advanced germ cell cancer tumors of the testis. Eur Urol (2007) 0.75
Editorial comment. Eur Urol (2006) 0.75
New therapies in renal cell carcinoma. Curr Opin Support Palliat Care (2007) 0.75
Androgen deprivation therapy for node-positive prostate cancer: adjuvant does not mean salvage. J Clin Oncol (2009) 0.75
Editorial Comment to Maintenance monotherapy with gemcitabine after standard platinum-based chemotherapy in patients with advanced urothelial cancer. Int J Urol (2015) 0.75
[Radiotherapy and inhibitors of epidermal growth factor receptor: preclinical findings and preliminary clinical trials]. Bull Cancer (2003) 0.75
Neoadjuvant chemotherapy in muscle-invasive bladder cancer: ready for prime time? Crit Rev Oncol Hematol (2012) 0.75
[Neoadjuvant chemotherapy for urothelial tumors]. Rev Prat (2014) 0.75
[Prostatic cancer and pelvic node involvement: a unambiguous disease?]. Prog Urol (2006) 0.75
[Towards the individualisation of prescriptions in oncology: urogenital cancers]. Bull Cancer (2008) 0.75
[Clinical practice guidelines: Standards, Options and Recommendations for the diagnosis of carcinomas of unknown primary site]. Bull Cancer (2003) 0.75
Familial primary mediastinal nonseminomatous germ-cell tumors. Urol Oncol (2004) 0.75
Vemurafenib as a neoadjuvant therapy in advanced melanoma: local tumour control, but no prevention of metastatic relapse. Eur J Dermatol (2013) 0.75
Systemic chemotherapy in patients with advanced transitional cell carcinoma of the urothelium and impaired renal function. Anticancer Drugs (2012) 0.75
A pilot study of gemcitabine in combination with oxaliplatin and vinorelbine in patients with metastatic bladder cancer. Anticancer Res (2010) 0.75
[Prognostic factors in localized and in metastatic renal cell carcinomas]. Prog Urol (2007) 0.75
[Updates on gemcitabine at the American Society of Clinical Oncology congress (ASCO, 2002) ]. Bull Cancer (2002) 0.75
[Prostate cancer and acute disseminated intravascular coagulation. Therapeutic management based on three cases]. Prog Urol (2003) 0.75
Gemcitabine and cisplatin after radical cystectomy for bladder cancer in an adjuvant setting: feasibility study from the Genito-Urinary Group of the French Federation of Cancer Centers. Anticancer Drugs (2006) 0.75
[Treatment of anaemia in medical oncology]. Orv Hetil (2012) 0.75
Targeted therapies in metastatic renal cell carcinoma: the light at the end of the tunnel. Expert Rev Anticancer Ther (2006) 0.75
[Management of metastatic bladder cancer]. Rev Prat (2014) 0.75
[Bladder cancer and urothelial tumors. New therapeutic strategies]. Rev Prat (2014) 0.75
[Testicular tumors]. Rev Prat (2014) 0.75
[Systematic review 2007: Primary treatments of testicular germ cell tumors after radical orchydectomy]. Bull Cancer (2008) 0.75
In vitro cytotoxic effect of melphalan and pilot phase II study in hormone-refractory prostate cancer. Anticancer Res (2006) 0.75
Modeling plasma and saliva topotecan concentration time course using a population approach. Oncol Res (2003) 0.75
[Intrathecal methotrexate chemotherapy for leptomeningeal carcinomatosis]. Orv Hetil (2012) 0.75
[Role of mitoxantrone in the treatment of hormone-independent metastatic cancer of the prostate]. Prog Urol (2002) 0.75
[Urachal cancers]. Bull Cancer (2013) 0.75